<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03291210</url>
  </required_header>
  <id_info>
    <org_study_id>TAVI-O2</org_study_id>
    <nct_id>NCT03291210</nct_id>
  </id_info>
  <brief_title>O2 Tension During TAVI</brief_title>
  <official_title>Effect of O2 Tension on Myocardial Injury During TAVI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperoxemia can produce various complications including oxidative stress and myocardial
      injury. We hypothesized that the normoxic group would have lower myocardial injury compared
      to hyperoxic group after transcatheter aortic valve replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperoxemia can produce various complications, such as excessive oxidative stress,
      hyperoxia-induced vasoconstriction, increased perfusion heterogeneity, and resultant
      myocardial injury. Previous studies have been observed higher mortality in patient group
      maintained with supranormal oxygenation after resuscitation from cardiac arrest. However, the
      effect of hyperoxia vs. normoxia on myocardial injury during transcatheter aortic valve
      replacement (TAVR) has not been well investigated. We hypothesized that the normoxic group
      would have lower myocardial injury compared to hyperoxic group after TAVR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Anticipated">October 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Troponin I</measure>
    <time_frame>72 hours after the end of procedure</time_frame>
    <description>Area under the curve of troponin I</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CK MB</measure>
    <time_frame>72 hours after the end of procedure</time_frame>
    <description>Area under the curve of CK MB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cerebral oximetry</measure>
    <time_frame>through procedure completion, an average of 3 hours</time_frame>
    <description>changes in cerebral oximetry during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirum</measure>
    <time_frame>through admission completion, an average of 5 days</time_frame>
    <description>Newly onset delirium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AKI or RRT</measure>
    <time_frame>through admission completion, an average of 5 days</time_frame>
    <description>Newly onset acute kidney injury or renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke, myocardial infarction or mortality</measure>
    <time_frame>through admission completion, an average of 5 days</time_frame>
    <description>Newly onset stroke, myocardial infarction or mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Troponin</condition>
  <arm_group>
    <arm_group_label>Normoxemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the normoxemia group receives inspired oxygen fraction of 0.3 from initiation of induction of anesthesia to the end of the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperoxemia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the hyperoxemia group receives inspired oxygen fraction of 0.8 from initiation of induction of anesthesia to the end of the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal inspired oxygen fraction</intervention_name>
    <description>receives inspired oxygen fraction of 0.3</description>
    <arm_group_label>Normoxemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high inspired oxygen fraction</intervention_name>
    <description>receives inspired oxygen fraction of 0.8</description>
    <arm_group_label>Hyperoxemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for transcatheter aortic valve replacement due to aortic stenosis

        Exclusion Criteria:

          -  Transapical approach

          -  Pre-procedural PaO2 &lt; 65 mmHg or oxygen support therapy

          -  Pre-procedural severe kidney injury (end-stage renal disease)

          -  Pre-procedural chronic pulmonary disease, symptomatic asthma

          -  Pre-procedural Tb-destroyed lung

          -  Lung cancer

          -  History of acute coronary syndrome within 6 months

          -  History of stroke or transient ischemic attack within 6 months

          -  Refuse to participate

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunseok Jeon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunseok Jeon, MD, PhD</last_name>
    <phone>82-2-2072-2465</phone>
    <email>jeonyunseok@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Youn Joung Cho, MD</last_name>
    <phone>82-2-2072-2469</phone>
    <email>mingming7@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunseok Jeon, MD, PhD</last_name>
      <phone>82-2-2072-2467</phone>
      <email>jeonyunseok@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yunseok Jeon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yunseok Jeon</investigator_full_name>
    <investigator_title>Prinicipal investigator</investigator_title>
  </responsible_party>
  <keyword>hyperoxemia</keyword>
  <keyword>myocardial injury</keyword>
  <keyword>transcatheter aortic valve replacement</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

